Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
In patients with hepatorenal syndrome (HRS), 4-hr administration of a vasopressin analog has recently been shown to benefit renal blood flow and renal function. However, long-term effects and tolerance of this treatment have not been reported. We report a case of HRS that was controlled by the vasopressin analog, terlipressin. Because HRS repeatedly relapsed when treatment was discontinued, terlipressin, 2 mg/day was administered for 67 days, until liver transplantation could be performed in a patient with normal renal function. Except for limited cutaneous necrosis at an injection point, prolonged treatment with this vasopressin analog was well tolerated.
Ganne-Carrié
N
N
Service d'Hépatologie, H pital Beaujon, Clichy, France.
Hadengue
A
A
Mathurin
P
P
Durand
F
F
Erlinger
S
S
Benhamou
J P
JP
D000328:Adult; D005260:Female; D006530:Hepatorenal Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007262:Infusions, Intravenous; D016031:Liver Transplantation; D008236:Lypressin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077585:Terlipressin; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin